Imipenem monohydrate, 98%

Imipenem monohydrate,Tienam, Primaxin, CAS # 74431-23-5 is a broad-spectrum carbapenem antibiotic that interferes with the activity of penicillin binding proteins along the inner cell wall.

製品番号（カタログ番号）	数量
455322500	250 mg

製品番号（カタログ番号） 455322500

価格（JPY）

250 mg

一括またはカスタム形式をリクエストする

化学物質識別子

CAS74431-23-5

Appearance (Color)Off-white to light yellow

HPLC>=97.5 %

Appearance (Form)Powder

Water5 to 8 %

Infrared spectrumConforms

This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

General description
• Imipenem monohydrate is a beta-lactam derived from the compound thienamycin, produced by Streptomyces cattleya
• Disrupts cell wall integrity, preventing cell division and promoting lysis by interfering with the activity of penicillin binding proteins
• Imipenem is a third-generation cephalosporin that can kill both gram-negative and gram-positive bacteria

Applications
• Suitable for the study of antibiotic resistance
• High-quality, laboratory grade for use in vitro and in vivo experiments

RUO – Research Use Only

Literature references

Pericàs, J.M.; Moreno, A.; Almela, M.; García-de-la-Mària, C.; Marco, F.; Muñoz, P.; Peña, C. de Alarcón, A.; Del Río, A.; Eworo, A.; Cruceta, A.; Paré, J.C.; Mestres, C.A.; Miró, J.M. FOSIMI Investigators. Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial. Clin Microbiol Infect. 2018, 24(6), 673-676.

Chavan, V.V.; Dalal, A.; Nagaraja, S.; Thekkur, P.; Mansoor, H.; Meneguim, A.; Paryani, R.; Singh, P.; Kalon, S.; Das, M.; Ferlazzo, G.; Isaakidis, P. Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges. PLoS One. 2020, 16;15(6), e0234651.